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ARTICLE
Resistance to checkpoint blockade therapy through
inactivation of antigen presentation
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Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged
responses in patients with metastatic melanoma, but the common mechanisms of primary
and acquired resistance to these agents remain incompletely characterized and have yet to
be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic
melanoma patients treated with CPB therapies, we observed point mutations, deletions or
loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC
class I antigen presentation, in 29.4% of patients with progressing disease. In two inde-
pendent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively,
we ﬁnd that B2M LOH is enriched threefold in non-responders (~30%) compared to
responders (~10%) and associated with poorer overall survival. Loss of both copies of B2M is
found only in non-responders. B2M loss is likely a common mechanism of resistance to
therapies targeting CTLA4 or PD1.
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A lthough immune checkpoint blockade (CPB) with ipili-mumab (anti-CTLA4), pembrolizumab and nivolumab(anti-PD1), and atezolizumab (anti-PDL-1), leads to
prolonged responses in 15–40% of patients with metastatic mel-
anoma, treatment refractory disease, and progression after initial
response remain major causes of mortality1–3. Checkpoint inhi-
bitors are designed to unleash tumor-speciﬁc T-cell immunity by
targeting co-inhibitory receptors and their ligands, and have been
approved by the FDA for the treatment of metastatic
melanoma4, 5 and other types of solid tumors6. More speciﬁcally,
the efﬁciency of CPB depends on cytotoxic CD8+ T-cell (CTL)
recognition of cancer-speciﬁc antigens presented on human leu-
kocyte antigen (HLA) class I complexes, which are composed of a
heavy-chain and beta-2-microglobulin (B2M), a crucial factor
required for to the assembly of all HLA class I complexes and for
the stable presentation of antigens by the tumor cells7.
A deeper understanding of the mechanisms underlying
response and resistance to CPB, coupled with more effective
predictive biomarkers, would enable earlier detection of pro-
gressive disease and inspire new therapeutic strategies that induce
long-term responses. To date, several clinical predictors of CPB
response in melanoma have been identiﬁed (e.g., mutational and
neoantigen loads, PDL-1 expression), with PDL-1 expression
being used in practice to select patients for therapy8–10. In pre-
treatment tumor samples, defects in the IFN γ pathway11 were
identiﬁed as a mechanism of primary resistance to anti-CTLA4
therapy. Moreover, in post-treatment samples, mutations in
JAK1, JAK2, and B2M were recently proposed as mechanisms of
acquired resistance in three melanoma patients treated with anti-
PD-112. Despite these advances, the basis for lack of response and
resistance to different CPB remains unknown in most patients
and has not been studied in large cohorts. We hypothesized that
the strong immune pressure imposed by different CPB therapies
on tumor populations could lead to the selection of common
mechanisms of resistance, enabling the tumor to evade immune
destruction.
To ﬁnd common mechanisms of intrinsic and acquired resis-
tance to CPB therapy, we analyzed somatic genetic alterations in
longitudinal samples in a cohort of patients treated with several
CPB and validated our results in two large cohorts. While we ﬁnd
no signiﬁcant changes in both mutational and neoantigen loads
over time between responders and non-responders, we identify
B2M aberrations in 29.4% of patients with progressing disease,
including multiple early frameshift mutations, LOH overlapping
B2M, and absence of tumor-speciﬁc B2M protein expression.
Additional defects in the antigen presentation and IFNγ pathways
are identiﬁed but are not restricted to progressing lesions in our
cohort. In two independent cohorts of 105 and 38 melanoma
patients treated with ipilimumab (anti-CTLA4) and pem-
brolizumab (anti-PD1), respectively, we ﬁnd that B2M LOH is
enriched threefold in non-responders (~30%) vs. responders
(~10%) and associated with poorer overall survival (log-rank p=
0.01, p= 0.006). Loss of both copies of B2M is found only in non-
responders. We also ﬁnd evidence for association of LOH over-
lapping IFNGR1 with poorer overall survival exclusively in the
anti-PD1 cohort. Overall, these results imply that B2M loss is a
common mechanism of intrinsic and acquired resistance to CPB
inhibitors, and should stimulate development of new therapeutic
strategies.
Results
Genetic analysis of longitudinal biopsies. To dissect the genetic
alterations associated with intrinsic and acquired resistance, we
performed WES on 49 longitudinal tumor (and matched blood)
samples from 17 patients with metastatic melanoma, 10 of whom
initially responded to CPB, with 5 having durable responses and 5
who eventually progressed (Supplementary Data 1 and Supple-
mentary Fig. 1). Frequency of cancer cells with mutations in 22
known melanoma drivers remains relatively constant over time,
suggesting minimal contribution to CPB escape13 (Supplemen-
tary Fig. 2). While a positive correlation between objective
response and survival was observed in our cohort, genome-wide
analysis showed no signiﬁcant differences in the overall mutation
load (Supplementary Fig. 3) or neoantigen load (Supplementary
Figs. 4 and 5) over time or between responders and non-
responders, consistent with previously observed weak
associations8, 14. Similarly, we saw no signiﬁcant difference in
somatic mutation loads in genes related to the HLA presentation
(Supplementary Fig. 6) or interferon-gamma pathways (Supple-
mentary Fig. 7), which have been recently implicated as both
primary and acquired resistance mechanisms to CPB11, 12.
The lack of a positive correlation between response and somatic
mutation burden in these two pathways could be due to
the limited cohort size or to aggregation of all mutations,
thus masking a subset of mutations associated with clinical
outcome.
Acquired resistance through the loss of B2M. As the genetic
landscape over the entire cohort was insufﬁcient to explain
patient outcome, we next performed a focused case study. From
the ﬁve patients with initial response followed by disease pro-
gression, we focused on Pat208 who showed a response lasting
more than 6 months and had a total of six high-quality biopsies at
baseline, disease regression, and disease progression (Fig. 1a). To
identify potential drivers of resistance in Pat208, we looked for
genes showing mutations concurrent with loss of heterozygosity
(LOH) that were present at high cancer cell fractions only during
progressive disease but not while the patient was responding. Of
248 mutations with adequate coverage across all samples
(detection power ≥0.9) (Supplementary Data 2), only B2M
mutations satisﬁed all criteria (Fig. 1b). Speciﬁcally, we found two
frameshift mutations in exon-1 of B2M: p.Leu13fs and p.Ser14fs
and conﬁrmed the presence of these mutations only during
progression by targeted Sanger sequencing and manual review of
sequenced reads at the B2M locus (Supplementary Figs. 8 and 9).
In the same patient, chromosome 15 segment copy ratios show
similar breakpoints in all progression samples, indicating a single
B2M deletion event preceding the acquisition of p.Leu13fs and p.
Ser14fs (Fig. 1c). Due to this deletion/LOH and upstream fra-
meshift mutations in B2M, the majority of cancer cells in pro-
gression samples were likely to be B2M deﬁcient.
The spatial distribution and population frequency of the two
B2M mutations suggest that a tumor lineage diverged early,
developed B2M LOH, and branched into two separate CPB-
resistant populations, each with a distinct early frameshift in
B2M. Despite the spatial proximity of post-Tx-II-1 and post-Tx-
II-2 (Fig. 1a), p.Ser14fs was only detected in post-Tx-II-2 (74% of
cancer cells) and not post-Tx-1 (0%). In contrast, p.Leu13fs was
high only in post-Tx-II-1 (55%) but not in post-Tx-II-2 (1%)
(Fig. 1b and Supplementary Fig. 9). Phylogenetic reconstruction
using all mutations found in Pat208 biopsies resulted in two
major lineages branching early in the tumor’s evolutionary
history. Biopsies taken before progressive disease were composed
of lineages on the left branch, while biopsies taken after
progressive disease were composed of lineages on the right
branch (Supplementary Fig. 10). While this pattern could be
attributed to spatial heterogeneity of lesions, the absence of
lineages from the left branch of the tree in all four progression
biopsies and the dominance of new B2M-deﬁcient lineages
suggest that B2M loss led to signiﬁcant selective advantages.
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These results support the idea of immunoediting15 as a
mechanism of resistance to CPB, were the “immunogenic” tumor
cells have been edited by the immune system, enabling the B2M-
deﬁcient (“non-immunogenic”) clones to evade immune
destruction.
To explore whether genetic alterations in B2M led to loss of
protein expression, immunohistochemistry (IHC) was performed
on Pat208 biopsies. As expected from the identiﬁed B2M
frameshift mutations, a dramatic drop in tumor-speciﬁc B2M
protein levels occurred after Pat208-developed resistance (Fig. 1d).
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Since B2M is essential to the assembly of all HLA class I
complexes and for the stable presentation on the cell surface7, we
next examined HLA class I expression by staining biopsy samples
with pan-HLA class I antibodies in Pat208. While HLA class I
proteins localized appropriately to the outer cell membrane of
melanoma cells during response to CPB, they were not detected
on the outer membrane during disease progression (Supplemen-
tary Fig. 11a). The presence of simultaneous LOH and frameshift
B2Mmutations in Pat208, along with concurrent loss of B2M and
HLA Class I protein expression, suggests that B2M aberrations
could contribute to tumor evasion of CD8+ T-cell responses and
disease progression.
Changes in the tumor microenvironment during relapse.
Because checkpoint therapy depends on CTL recognition of
tumor antigens presented on HLA class I proteins4, 16, we
monitored changes in the immune cell inﬁltrate of tumors from
Pat208. Based on RNA sequencing of bulk tumor biopsies (Fig. 2a
and Supplementary Data 3), transcript levels of genes involved in
antigen presentation, co-stimulation, inﬂammation, cytotoxicity,
and CD8+ and NK cells increased during regression and subse-
quently decreased with progression. In agreement with bulk
expression data, staining of biopsy sections (Fig. 2b) showed a
dramatic decrease in CD8+ TILs, and to a lesser extent CD4+
TILs, during progressive disease, suggesting that, non-inﬂamed
B2M-deﬁcient tumors are less susceptible to inﬁltration by
cytotoxic T cells.
B2M defects in additional patients with progressing disease.
Several other patients in our cohort exhibited B2M alterations.
We discovered two B2M frameshift mutations, p.Ser14fs (50–90%
of cancer cells) and p.Gly63fs (70–90% of cancer cells), in pro-
gression samples of PatT33, who initially responded for 1 year to
ipilimumab. At baseline, p.Gly63fs was detected in 1/429 reads,
and p.Ser14fs was undetectable (0/475); however, due to the low
tumor purity of this baseline sample, no conclusions can be
drawn about how these two mutations evolve with progression.
The presence of multiple frameshift mutations in B2M found
in Pat208 and PatT33 suggested that this might be a mutation
hotspot. Indeed, TCGA mutation data showed a cluster of B2M
mutations at Ser14 (Supplementary Fig. 12a). All B2M mutations
found in this cohort lie within 4× dinucleotide repeats
(Supplementary Fig. 12b), some of which were seen in high-
level microsatellite instability colorectal cancers17, 18, thus
implicating faulty DNA mismatch repair (MMR). No DNA
mutations in MMR (MLH1, MSH2, MSH3, MSH6, and PMS2)
were found in Pat208. A somatic mutation in MSH2, p.P476S,
was found in post-Tx and post-Tx-II samples of PatT33.
In addition to B2M mutations found in Pat208 and PatT33,
LOH that includes B2M was observed in all samples of Pat99, a
patient who progressed after a brief 2.5-month period of
regression following treatment with nivolumab (anti-PD1)
(Fig. 3a). Tissue staining showed loss of tumor-speciﬁc B2M
protein expression during and after progressive disease, but not
while the patient was responding (Fig. 3b). Similar to Pat208,
tissue staining for CD4+ and CD8+ T cells in Pat99 (Supplemen-
tary Fig. 13) showed a dramatic decrease in CD8+ TILs, and to a
lesser extent CD4+ cells, during progressive disease after B2M loss
but not during response. Two more non-responders, Pat25 and
Pat115, had LOH that includes B2M (Supplementary Fig. 14). In
contrast to Pat99, loss of tumor-speciﬁc B2M protein expression
was found in all samples from Pat25 (Fig. 3c). In addition, in
Pat99 and Pat25, HLA class I was localized to the cytosol during
disease progression (Supplementary Fig. 11). No slides were
available for Pat115. Validation of B2M expression in a responder
(Pat272) showed no changes in tumor-speciﬁc expression over
time (Fig. 3d). We conclude that in addition to genetic mutations
leading to loss of B2M (e.g., Pat208), other non-genetic
mechanisms also use by tumor cells (e.g., Pat99 and Pat25) and
may lead to transient or long-term reduction in antigen
presentation.
Collectively, 5 out of 17 patients (29.4%) in our cohort
exhibited B2M defects, with three of ﬁve patients who initially
responded and then progressed (Pat208 with LOH and FS
mutation; Pat33 with FS mutations; Pat99 with LOH), and two of
seven non-responders (Pat25 and Pat115 with LOH) (Supple-
mentary Data 1). No B2M alterations were detected in responders
within our cohort. We also found that sequencing of cell-free
DNA isolated from blood samples detected B2M frameshifts in
Pat208 and B2M LOH in Pat99 (Supplementary Fig. 15).
Although sequencing cell-free DNA from blood samples may
not be sensitive enough when tumor burden is low, it does
provide a minimally invasive way of monitoring resistance
mutations for patients receiving CPB.
Defects in the antigen presentation and IFNγ pathways. Since
JAK1, JAK2, and IFNGR1 were recently implicated as drivers of
acquired or primary resistance to anti-PD1 and anti-CTLA4
therapies, respectively11, 12, we looked at the frequency of
mutations and LOH in these genes within our cohort. We found
six JAK1 alterations, including a missense mutation in one non-
responder, and LOH in ﬁve more patients (two non-responders,
two resistant patients, and one responder), including PatT33, who
developed resistance to CPB and also had two B2M frameshift
mutations. LOH overlapping JAK2 was detected in 10 samples (4
non-responders, 3 resistance patients, and 3 responders), and
Fig. 1 Loss of B2M is associated with resistance in a patient treated with checkpoint blockade. a Treatment and sample collection timeline for Pat208. Row
1, computed tomographic (CT) images of right thigh taken at baseline, during response and relapse; row 2, CPB treatments (ipilimumab—anti-CTLA4,
pembrolizumab—anti-PD1); row 3, clinical response while on treatment, with blue indicating regression and orange indicating progression; row 4, days
elapsed with respect to the start of treatment; row 5, location of biopsies taken at the different time points. b Criteria used to identify potential drivers of
resistance, were genes with multiple non-silent mutations and LOH that are dominant only during disease progression. Out of 248 mutations with
adequate coverage across all samples (detection power ⩾0.9), only B2M mutations satisﬁed all criteria (upper panel). Fraction of cancer cells harboring
two separate early frameshift mutations in B2M (p.Leu13fs and p.Ser14fs) detected in Pat208. Blue backgrounds indicate samples taken during disease
regression, and orange backgrounds indicate samples taken during disease progression. Error bars indicate 95% conﬁdence intervals as inferred by
ABSOLUTE (lower panel, described in “Methods” section). c Illustration of the deletions locations on chromosome 15 overlapping the B2M locus found in
Pat208, as well as the location of the two early frameshift mutations relative to the B2M gene (blue line); and the total copy ratios of target regions on
chromosome 15 in each biopsy. Red dashed lines indicate an absolute total copy number of 2 as inferred by ABSOLUTE. A deleted region overlapping the
B2M locus is seen in all relapse samples (light orange background). d Samples were stained with an antibody cocktail for melanoma cells (mel.cocktail)
using anti-melanosome (HMB45), anti-MART-1/melan A and anti-Tyrosinase, to discern melanoma cells from normal cells; or with an antibody speciﬁc for
B2M. Colored boxes indicate B2M expression scores: B2M scoring was estimated by using four different levels of expression in the tumor fraction: minimal,
0–10%; low, 10–50%; intermediate, 50–80%; and high, 80–100%, B2M expression in the tumor fraction. Original magniﬁcation ×100
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01062-w
4 NATURE COMMUNICATIONS |8:  1136 |DOI: 10.1038/s41467-017-01062-w |www.nature.com/naturecommunications
Cytotoxicity
0.0
2.5
5.0
7.5
10.0
B cells
0
1
2
3
4
CD4 Treg
0
5
10
CD4/ CD8 T cells
0
30
60
90
Macrophages/ Neutrophils
0
10
20
30
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Melanoma
0
200
400
600
NK cells
0.000
0.005
0.010
0.015
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
pDCs
0
2
4
6
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Stress ligands
0.0
0.2
0.4
0.6
Chemokines
0.00
0.25
0.50
0.75
1.00
CD4
CD8
Macrophages
Neutrophils
Th cell-related TFs
0
10
20
30
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
TH2
TH1
T-cell activation/exhaustion
0
5
10
15
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Exhaustion markers
Activation markers
Co-stimulatory/
co-inhibitory receptors
0
2
4
6
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Co-inhibitory
Co-stimulatory
Antigen presentation machinery
Lo
g-
av
er
ag
e 
TP
M
 s
co
re
s 
fo
r g
en
e 
se
t
Lo
g-
av
er
ag
e 
TP
M
 s
co
re
s 
fo
r g
en
e 
se
t
Lo
g-
av
er
ag
e 
TP
M
sc
o
re
s 
fo
r g
en
e 
se
t
0
20
40
60
80
0
200
400
600
Pro-inflammatory TF
0
3
6
9
12
Cytokines
0
2
4
6
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Pre
-Tx
Po
st-
Tx
Po
st-
Tx
 II
Po
st-
Tx
 III
Disease regression
Disease progression
Pre
-Tx
Regression Progression
Treatment
Biopsy location
Clinical response
0 60 120 180 240 300 360 420 480Days after treatment
CD
8
CD
4
0
200
400
600
800
1000
N
um
be
r o
f t
um
or
in
filt
ra
tin
g 
CD
8 
T 
ce
lls
0
100
200
300
400
N
um
be
r o
f t
um
or
in
filt
ra
tin
g 
CD
4 
T 
ce
lls
B2
M
M
e
la
no
m
a 
co
ck
ta
il
Im
m
un
e 
ce
ll 
ty
pe
s 
Tu
m
or
 m
ic
ro
en
vi
ro
nm
en
t 
Im
m
un
e 
ce
ll 
st
at
e
a
b
Minimal
(0–10%)
High 
(80–100%)
B2M expression
scores
Low 
(10–50%)
Intermediate
(50–80%)
Anti-inflammatory
Pro-inflammatory
B2M only
Antigen presentation machinery
Pembrolizumab  Ipilimumab
Fig. 2 Dissecting the tumor microenvironment during disease regression and progression. a Expression scores of genes related to the tumor
microenvironment, immune cell types, or immune cell states. Expression scores were calculated as the geometric mean of TPM values of genes in
Supplementary Data 3. Blue backgrounds indicate biopsies taken during disease regression, and orange backgrounds indicate biopsies taken during disease
progression. b Samples for each time point from Pat208 were stained with speciﬁc antibodies against CD8 or CD4 and were quantiﬁed using the cell
counter function in Fiji (described in “Methods” section). Boxes areas in the upper panels (CD4 and CD8, original magniﬁcation ×100) are shown at higher
magniﬁcation (×200) in the lower panels (melanoma cocktail and B2M). Colored boxes indicate B2M expression scores: B2M scoring was estimated by
using four different levels of expression in the tumor fraction: minimal, 0–10%; low, 10–50%; intermediate, 50–80%; and high, 80–100%, B2M expression
in the tumor fraction. A timeline of treatment, clinical response, and biopsy locations is shown at the top
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LOH overlapping IFNGR1 was detected in 5 samples (3 non-
responders, 1 resistant patient, and 1 responder) (Supplementary
Data. 4). We did not detect any mutations in JAK2, IFNGR1, and
IFNGR2 within our 17 patient cohort, but identiﬁed alterations in
other genes related to the antigen presentation and IFNγ
machineries (e.g., STAT1, STAT2, TAP1, and TAP2), which were
not restricted to progressing samples. Although only B2M
alterations were exclusively present in non-responders within our
cohort, the mutations observed in the interferon pathway may
also contribute to immune evasion by tumor populations in
response to CPB.
Detection of B2M aberrations in two independent cohorts.
Next, we validated the clinical importance of B2M aberrations in
two independent cohorts. In the ﬁrst cohort composed of biopsies
from 110 patients prior to anti-CTLA4 therapy8, we found B2M
aberrations to be a signiﬁcantly enriched in non-responders and
signiﬁcantly associated with poorer survival. After ﬁltering out
ﬁve biopsies with low tumor content, this data set was composed
of 26 responders, 69 non-responders, and 10 patients who were
deﬁned as long-term survivors with no objective clinical response
(Fig. 4a, Van Allen data set). Two frameshift and one missense
B2M mutations, including p.Leu13fs, were discovered in three
non-responders, but not in any responders (Fig. 4b). In all three,
B2M LOH also occurred, leading to complete loss of B2M. As our
data implicated LOH as a more frequent form of B2M alteration
and a potential precursor to the loss of B2M protein expression,
we investigated the presence of B2M LOH in this large cohort.
B2M LOH events were signiﬁcantly enriched in non-responders
(20/69, 28.9% vs. 4/36, 11.1%, one-sided Fisher’s exact p= 0.03),
and signiﬁcantly associated with poorer overall survival (log-rank
p= 0.01) (Fig. 4c). Similarly, in the second cohort composed of
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Fig. 4 Clinical relevance of B2M aberrations in two independent cohorts. a Analysis workﬂow for both Van Allen (105 patients pre-anti-CTLA4 treatment)
and Hugo (38 patients pre-anti-PD1 treatment) data sets. For both data sets, we analyzed whole exome sequences of paired tumor and normal biopsies
using the same pipeline used to analyze our cohort. b Illustration of three non-responders in the Van Allen data set with nucleotide mutations in B2M
accompanied by loss of the wild-type allele. Gaps in the top chromosome depict the deleted region in each patient. Exons in B2M are shown as a horizontal
blue rectangle, with mutations found in each patient highlighted in red. c Kaplan–Meier survival curves for patients in the Van Allen data set with (red) and
without (black) B2M LOH. Log-rank p value is shown (p< 0.01). Inset shows the frequency of patients with B2M LOH in non-responders vs. responders and
long-term survivors. One-sided Fisher’s exact p value is shown (p< 0.03). d Identical analysis performed for the Hugo data set as in c
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biopsies from 21 responders and 17 non-responders (n= 38)
before anti-PD1 treatment14 (Fig. 4a, Hugo data set), we found
B2M LOH to be signiﬁcantly associated with a worse overall
survival (log-rank p= 0.006) (Fig. 4d). B2M LOH was not sig-
niﬁcantly enriched (Fisher’s exact test), although the proportion
of patients with B2M LOH was very similar to our and the Van
Allen cohort (non-responders 5/17, 29.4% vs. responders 2/21,
9.5%) (Fig. 4d). No nucleotide mutations were found in this data
set, consistent with the frequency at which B2M nucleotide
mutations were seen in the Van Allen data set. Unlike B2M, LOH
in genes involved in the IFNγ and antigen presentation pathway
were not signiﬁcantly enriched in non-responders, and did not
signiﬁcantly associate with poorer overall survival across both
data sets, except for LOH in IFNGR1 that was signiﬁcantly
associated with lower overall survival only in the Hugo data set
(Supplementary Data 4 and Supplementary Fig. 16). In contrast
to B2M, mutations in IFNGR1, JAK1, JAK2, STAT2, and TAP1/2
were found in both non-responders and responders in these two
independent cohorts. Given the enrichment of B2M aberrations
in non-responders and their signiﬁcant association with lower
overall survival, and given the validation of these ﬁndings in three
cohorts treated with different CPB therapies, we suggest that
LOH and mutations in B2M contribute to a common mechanism
of resistance to various CPB therapies.
NK cell control the expansion of B2M-deﬁcient clones. Finally,
an important clinical question is whether B2M-deﬁcient mela-
nomas can be targeted with NK cells, given the known inhibitory
effect of HLA class I proteins on NK cells19, 20. We thus devel-
oped a mouse model to test whether natural killer cells would
selectively kill B2M-deﬁcient melanoma cells. Using the CRISPR/
Cas9 technology, we introduced a guide RNA and deleted B2M in
a melanoma cell line derived from BRAFV600E; PTEN−/− trans-
genic mice (Supplementary Fig. 17a, b). To mimic evolving
human tumors, we transplanted a mixture of the parental
B2M+/+ and the B2M-deleted cell lines (each tagged with unique
markers) into mice in the presence or absence of NK cells (using
antibodies to deplete NK cells) (Supplementary Fig. 17c). Mice
that lacked NK cells showed a signiﬁcant increase in B2M-deleted
relative to B2M+/+ tumor cells (Supplementary Fig. 17d). Thus,
NK cells offer a potential strategy to overcome resistance caused
by loss of B2M.
Discussion
Recent studies have identiﬁed several genetic drivers of primary
or acquired resistance to CPB therapy, including one patient with
an acquired B2M mutation, but were restricted to one type of
therapy (either anti-CTLA4 or anti-PD1)11, 12. While non-LOH
B2M aberrations are rare in melanoma (1.7–4% of cases)13, B2M
functional loss has been hypothesized as a mechanism of immune
escape in some cancers including melanoma12, 17, 21, 22. Fur-
thermore, dinucleotide repeats in B2M become hotspots for fra-
meshift indels, especially in tumors with aberrant MMR genes, as
seen in high-level microsatellite instability colorectal cancers23.
Our demonstration of B2M mutations and LOH only in pro-
gression samples in our cohort (several CPB therapies, n= 17
patients, 49 longitudinal samples) as well as enrichment of B2M
LOH in non-responders with poorer overall survival in two
independent cohorts (anti-CTLA4, n= 105; anti-PD1, n= 38),
suggests that B2M-mutated tumor subclones are selected through
immunoediting earlier in tumor development, or under selective
pressure applied by CPB. Although several genes are responsible
for the processing, loading, and presentation of antigens, and
have been shown to be mutated in cancers24, no proteins can
substitute for B2M in HLA class I presentation, making the loss of
B2M an evolutionary attractive route for CPB resistance.
Additionally, the ﬁnding that B2M mutations exclusively are seen
in pretreatment samples from patients who did not respond to
CPB or in post-progression samples after initial response to CBP,
whereas mutations in other genes, such as JAK1, JAK2, IFNGR1,
STAT2, and TAP1/2, were seen in pretreatment samples from
responders and non-responders alike, highlights the potential
importance of B2M in CPB resistance. Finally, our data also
implicated LOH as a more frequent form of B2M alterations in
non-responders (as well as IFNGR1 solely in the Hugo anti-PD1
cohort). LOH in B2M might be the initial event toward complete
loss of the B2M gene, followed by MHC class I and antigen
presentation loss. Indeed, it has been shown that LOH on
chromosome 15 overlapping B2M is enriched in other types of
cancer, such as breast, bladder, and MSS colon carcinomas (53,
44, and 35%, respectively)25.
Several important questions remain to be addressed based on
these results. First, what is the role of epigenetic regulation in
suppressing B2M expression when only one copy of the gene is
missing or defective? Second, how frequently is the resistance,
primary or acquired, to CPB therapy explained by B2M muta-
tions and/or loss of B2M/HLA protein expression levels prior to
or during treatment? Third, will therapies that target NK cell
activation, such as the induction of NK-activating ligands on
tumor cells by radiation or DNA-damaging agents20, improve
outcomes of CPB by targeting resistant cells that are deﬁcient for
antigen presentation? As checkpoint blockade immunotherapy
has become a mainstay of cancer therapy, it is imperative that
future efforts build upon the work presented here to answer these
questions and improve outcomes for our patients.
Methods
Patients samples. Patients with metastatic melanoma provided written informed
consent for the collection of tissue and blood samples for research and genomic
proﬁling, as approved by the Dana-Farber/Harvard Cancer Center Institutional
Review Board (DF/HCC Protocol 11–181). Matched tumor and normal blood
samples were obtained from 17 patients at baseline and after CPB treatment.
WES sequencing. Whole exome sequencing of DNA extracted from fresh frozen
tumors and matched normal blood samples was done as previously described8, 26.
All procedures were done at the Genomics Platform of the Broad Institute of
Harvard and MIT.
DNA was extracted using Qiagen AllPrep DNA/RNA Mini Kit (cat# 80204)
from fresh frozen tumor samples and stored at −80 °C. Germline DNA was
extracted from matched peripheral mononuclear cells. An aliquot of 250–500 ng of
DNA in 100 µl TE buffer was used as input for library generation. Palindromic
forked adapters (Integrated DNA technologies) with unique 8 base index molecular
barcode sequences were ligated to pool all samples. All other reagents used for end
repair, A-base addition, adapter ligation, and library enrichment PCR were
purchased from KAPA Biosciences in 96-reaction kits. After the post-library
enrichment process, solid phase reversible immobilization (SPRI) beads cleanup
(Beckman Coulter, cat# A63881) were used to reduce the volume to 20 µl to
maximize library concentration. Library concentrations were measured by an
automated PicoGreen assay on an Agilent Bravo instrument. All libraries above 40
ng/µl were considered acceptable for solution-phase hybrid selection and
sequencing.
Samples were hybridized using Agilent SureSelect Human All Exon Kit v2 as
previously described27. Samples were denatured at 95 °C, 5 min, then incubated at
65 °C, 17 h. DNA–RNA complexes were captured using the Agilent Bravo
instrument. The reaction was carried out using the SureSelect Target Enrichment
System Sequencing Platform Library Prep v2 (Agilent Technologies, cat# G3360-
90000), according to the manufacturer’s speciﬁcations.
Libraries were quantiﬁed and normalized using PicoGreen to ensure equal
concentration using a Perkin Elmer MiniJanus instrument and pooled by equal
volume on the Agilent Bravo instrument. Library pools were quantiﬁed using
quantitative PCR (KAPA Biosystems, cat# KK4832) with adapter-speciﬁc probes.
After qPCR, libraries were brought to 2 nM and denatured using 0.2 M NaOH on
the Perkin Elmer MiniJanus. After denaturation, libraries were diluted to 20 pM
using hybridization buffer (Illumina).
Cluster ampliﬁcation was performed according to the manufacturer’s protocol
(Illumina), HiSeq 2500 v4 cluster chemistry and ﬂowcells, as well as Illumina’s
Multiplexing Sequencing Primer Kit. Libraries were sequenced using the HiSeq
2500 v4 Sequencing-by-Synthesis method (paired end 76 bp reads) followed by
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analysis with RTA v.1.12.4.2. The minimum depth of coverage was 150× and 80×
for tumor and normal samples, respectively.
Whole transcriptome sequencing. Whole transcriptome sequencing was per-
formed as previously described8 using the Transcriptome Capture method. RNA
was extracted using Qiagen AllPrep DNA/RNA Mini Kit (cat# 80204) from fresh
frozen tumor samples and stored at −80 °C. An aliquot of 250 ng of puriﬁed total
RNA was used with DV200 scores >30%. First a stranded cDNA library form
isolated RNA was constructed followed by hybridization of the library to a set of
DNA oligonucleotide probes to enrich the library for mRNA transcript fragments
(capturing 21,415 genes, representing 98.3% of the RefSeq exome). The normalized,
pooled libraries were loaded onto HiSeq 2500 for a target of 50 million 2 × 76 bp
paired reads per sample.
Gene expression analysis. Whole transcriptome data were processed on Cancer
Genome Analysis tool “Firehose”. Alignment was performed using STAR28, and
de-duplication using Picard. Transcripts per million (TPM) values were calculated
using RSEM29. Expression scores in Fig. 2 were calculated as the geometric mean of
TPM values of genes in Supplementary Data 3.
Sanger sequencing. Genomic DNA extracted from Pat208 samples was used to
validate the WES c.(37–39)ctcfs, p.Leu13fs; and c.(40–45)tctcttfs, p.Ser14fs muta-
tions by using targeted Sanger sequencing. After DNA isolation, exon-1 in chro-
mosome 15, where the two mutations are located was ampliﬁed using primers
B2M_F (GGCATTCCTGAAGCTGACA) and B2M_R (GAAGTCACGGAGC-
GAGAGAG), followed by standard PCR conditions (95 °C 10 min; ×35 cycles (95 °
C 30 s, 58 °C 15 s, 72 °C 15 s); 72 °C 5min, 4 °C∞), using Platinum PCR Supermix
(Invitrogen, cat# 12532-016). Sanger sequencing was done using the B2M_R pri-
mer and was compared to normal control sample as a negative control.
Analysis of whole exome sequencing. Whole exome sequencing data were
processed sequentially via two pipelines. First, we used Picard (https://
broadinstitute.github.io/picard/), a tool developed by the Genomics Platform at the
Broad Institute, to process raw sequencing data from Illumina HiSeq. For each
tumor or normal sample, Picard checks for contamination, aligns reads to hg19,
and calculates quality metrics, resulting in a single de-multiplexed, aggregated
BAM ﬁle (see http://samtools.github.io/hts-specs/SAMv1.pdf). After Picard, BAM
ﬁles were processed using the Cancer Genome Analysis tool known as “Firehose”.
Firehose takes paired BAM ﬁles from matched tumor and blood samples, and
performs various functions, including quality control, local realignment, detection
of somatic single-nucleotide variations (SSNVs), and somatic copy number
alterations (SCNAs). Processing details involving Firehose have been detailed
elsewhere (see http://www.broadinstitute.org/cancer/cga)30.
SSNVs, and insertions and deletions (INDELs) were called using a consensus
voting algorithm that combined the outputs of Strelka31, VarDict32, and Mutect33.
Only SSNVs and INDELs called by at least two callers were kept. For each, the
union of all mutations found in each patient, reference, and alternate reads were
counted at each variant locus with a custom “force-calling” script. SSNVs within
coding regions of the genome were annotated for chromosomal location, variant
type, genome change, codon change, and protein change using Oncotator34. All
mutations called in B2M were manually veriﬁed in Integrative Genomics Viewer
(IGV). Various quality controls were used to ﬁlter out artifacts due to formalin
ﬁxation or oxidation during library preparation. SCNAs were detected using
Recapseg34, and allele-speciﬁc copy number variation was detected using
AllelicCapseg. Both tools are available on Firehose.
Due to variable tumor fraction of biopsies, it is important to normalize the
variant allele frequency, deﬁned as the frequency at which a variant is seen out of
the total number of reads at a position, to cancer cell fraction (CCF), the estimated
fraction of cancer cells containing the variant. We used ABSOLUTE35 to infer CCF
values for SSNVs and INDELs. In addition, ABSOLUTE also calculated ploidy,
purity, and absolute DNA copy numbers of SCNAs. The power to detect events
given sample purity and coverage was calculated by ABSOLUTE. Samples found to
be non-aberrant by ABSOLUTE (SCNAs were absent and thus could not be used to
determine optimal solutions during the manual curation step of ABSOLUTE) were
excluded from analysis.
We used PhyloWGS36 to reconstruct complete genotypes and phylogenetic
relationships of tumor subpopulations from CCF values of SSNVs, INDELs, and
SCNAs. PhyloWGS is capable of performing on both WES as well as whole genome
sequencing data (http://github.com/morrislab/phylowgs/issues/12). PhyloWGS
separates variants into simple somatic mutations (SSMs) and copy number
variations (CNVs). It corrects SSM frequencies in regions overlapping CNVs, and
models CNVs as pseudo-SSMs. PhyloWGS is based on a generative probabilistic
model. SSMS and CNVs are clustered using the non-parametric Dirichlet process
prior. The clonal evolutionary structure is modeled with the tree-structured stick-
breaking process prior. PhyloWGS then uses the Metropolis-Hastings algorithm, a
Markov chain Monte Carlo procedure, to sample phylogenies from the model
posterior that are consistent with SSM frequencies and evolutionary constraints.
For patients with more than 1000 mutational events, SSNVs and INDELs were
clustered in PhyloWGS without SCNAs. CCF values were normalized by respective
read depths and used as variant frequencies for input into PhyloWGS. Results for
Pat208 required manual curation due to the PhyloWGS algorithm’s propensity for
designating p.Leu13fs as the parent of p.Ser14fs, in violation of the “crossing rule”
outlined in the PhyloWGS paper as well as the ample evidence for a sibling
relationship between the two mutations. Thus, conﬁdence for p.Ser14fs was
artiﬁcially inﬂated by multiplying both the alternate and reference counts for the
corresponding SSM by 1000. The resulting subtree rooted at the population
containing p.Ser14fs was then merged back onto the original PhyloWGS output as
a sibling of the subtree rooted at the population containing p.Leu13fs. All events
assigned to the new subtree rooted at the population containing p.Ser14fs were
then removed from other populations elsewhere in the tree such that no event was
represented more than once.
Calculation of neoantigen load. POLYSOLVER (POLYmorphic loci reSOLVER)
was used to infer the HLA type for each patient, using sequencing data from the
matched peripheral blood sample37. Potentially antigenic peptide sequences were
inferred from mutational data. Neoantigen-binding predictions were made using
NetMHCPan38. Peptides were designated as strong binders (mutant peptide with
higher afﬁnity than 0.5% of random natural peptides, with corresponding wild-type
peptide having lower afﬁnity than 2% of random natural peptides) or weak binders
(mutant peptides with higher afﬁnity than 2% of random natural peptides, with
corresponding wild-type peptide having lower afﬁnity than 2% of random natural
peptides) with respect to the patient’s inferred HLA type. Mutated genes predicted
to give rise to at least one neoantigen were used to calculate the neoantigen load.
Visualization of TCGA data. Lollipop plots of B2M mutations found in TCGA
data sets were visualized using cbioportal (http://www.cbioportal.org/), using the
web query interface39, 40.
Histology and staining. Immunohistochemistry staining was performed on four
micrometer formalin-ﬁxed parafﬁn-embedded sections. All procedures were done
on the automated Ventana Discovery Ultra staining system. Sections were ﬁrst
deparafﬁnized with xylene and alcohol series, treated with EDTA retrieval solution
and blocked with discovery inhibitor (Ventana products). Sections were incubated
with primary antibodies for 16 min washed and incubated with a secondary
antibody conjugated with horseradish peroxidase for additional 16 min. Discovery
Purple Chromogen Kit (Ventana, cat# 760-229) was then applied to generate a
color reaction. Slides were then counterstained with hematoxylin (Ventana). Pri-
mary antibodies used for staining were: anti-B2M (Abcam, cat# ab27588; 1:1000);
anti-melanoma triple cocktail (HMB45 + A103 + T311; Ventana, cat# 790-4677;
1:100) containing the following antibodies: anti-Melanosome (HMB45), anti-
MART-1/melan A (A103), and anti-Tyrosinase (T311); anti-CD8 (SP57; Ventana,
cat# 790-4460; 1:150); anti-CD4 (SP35; Ventana, cat# 790-4423; 1:200), and anti-
HLA class I ABC (EMR8-5; Abcam, cat# ab70328; 1:100). Protocols for all the
staining are summarized in Supplementary Data 5. The anti-melanoma triple
cocktail was used to discern melanoma cells from normal cells, allowing B2M,
expression levels to be estimated for only the cancerous cell fraction. A single-blind
scoring of cancer-speciﬁc B2M and tumor inﬁltrating CD4+, CD8+ T cells
expression was conducted by two pathologists at the Massachusetts General
Hospital. B2M scoring was estimated by using four different levels of expression in
the tumor fraction: minimal, 0–10%; low, 10–50%; intermediate, 50–80%; and high,
80–100% B2M expression in the tumor fraction. Quantiﬁcation of tumor inﬁl-
trating CD8+ and CD4+ T cells was evaluated manually using a 20× digital image of
each case with the cell counter function in Fiji image processing software41.
Analysis of independent cohorts. Sequencing data in the BAM format from
tumor-normal pairs were analyzed using the identical pipeline for our cohort. In
looking at the statistical signiﬁcance of enrichment of B2M LOH in CPB non-
responders vs. responders and long-term survivors, we determined that Fisher’s
exact test was optimal due to the relatively small sample size and categorical nature
of our data. Fisher’s exact test reports the exact p value under a null hypothesis of
independent categories using the hypergeometric distribution. We determined the
log-rank test, which is commonly used to compare survival data between cohorts,
to be optimal for comparing the signiﬁcance in survival differences between
patients with and without LOH. The log-rank test assumes that data are right-
censored, which are appropriate for our clinical data. The log-rank test further
assumes a hypergeometric distribution of events (deaths) between patient groups at
each time point. Here the assumption that events occur independently is reason-
able. Here variance between groups is not applicable for categorical data. The
variance of the test statistic is based on the hypergeometric distribution.
Plasma cfDNA isolation and quantiﬁcation of genome equivalents. At least 10
ml of whole blood was collected by blood draw using EDTA as anticoagulant.
Plasma was separated within 5 h through two different centrifugation steps (the
ﬁrst at room temperature for 10 min at 1600×g and the second at 3000×g for the
same time and temperature), obtaining up to 3 ml of plasma. Plasma was stored at
−80 °C until cfDNA extraction. cfDNA was extracted from plasma using the
QIAamp Circulating Nucleic Acid Kit (QIAGEN) according to the manufacturer’s
instructions. An aliquot of 3 μl of cfDNA was used as template for each reaction.
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All samples were analyzed in duplicate. PCR reactions were performed using 10 μl
ﬁnal volume containing 5 μl LightCycler®480 SYBR Green I qPCR Master Mix, 2×
(Roche) and LINE-1 (12,5 μmol) forward and reverse primers. DNA at known
concentrations was also used to build the standard curve. Primer sequences are
available on request.
Droplet digital PCR. Measurement of FAM and HEX probes; gating was per-
formed based on positive and negative controls, and mutant populations were
identiﬁed. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-
Rad) to obtain fractional abundance of the mutant DNA alleles in the wild-type/
normal background. The quantiﬁcation of the target molecule was presented as
number of total copies (mutant plus WT) per sample in each reaction. Fractional
abundance is calculated as follows: F.A. %= (Nmut/(Nmut + Nwt)) × 100), where
Nmut is number of mutant events and Nwt is number of WT events per reaction.
Droplet digital PCR (ddPCR) analysis of normal control DNA (human genomic
DNA (Promega)) and no DNA template controls were always included. Leu13fs
WT: forward sequence: 5′-CCGAGATGTCTCGCTC-3′; reverse sequence: 5′-GGA
GGGTAGGAGAGACT-3′; probe sequence: 5′-CGCTACTCTCTCTTTCTGG-3′;
ﬂuorophore: HEX. Leu13fs del: forward sequence: 5′-CCGAGATGTCTCGCTC-3′;
reverse sequence: 5′-GGAGGGTAGGAGAGACT-3′; probe sequence: 5′-CGCTA
CTCTCTTTCTGGC-3′; ﬂuorophore: FAM.
Generation of mouse melanoma cell line deﬁcient for B2M. All lentiviruses were
made using 293T cells transfected with lentiviral vectors, psPAX2 (Addgene
12260), and pMD2.G (Addgene 12259) at a 10:10:1 ratio, using TransIT-LT1
reagent (MIRUS, MIR 2300) according to the manufacturer’s instructions. Mela-
noma cell line derived from BRAFV600E; PTEN−/− (BP) transgenic mice (a gift from
the laboratory of David Fisher, MGH, Cancer Center) were initially transduced
with the lentiCas9-EGFP virus (GPP Broad Institute, pXPR_BRD104) and
GFPhigh-positive cells were sorted to generate BPCas9+GFP+ cells. Cas9 activity was
evaluated prior to transduction with each of the lentiGuide viruses using the Cas9
activity assay vector (GPP Broad Institute, pXPR_BRD011). Next, BPCas9+GFP+
cells were transduced separately with a guide targeting B2M (5′-CACCG AGTA-
TACTCACGCCACCCAC-3′, 5′-AAACGTGGGTGGCGTGAGTATACTC-3′) or
a control guide against LacZ (5′-CACCGGTTCGCATTATCCGAACCAT-3′, 5′-
AAACATGGTTCGGATAATGCGAACC-3′), cloned into a lentiGuide-Puro
(pXPR_BRD003) or lentiGuide-Puro-Thy1.1 (modiﬁed pXPR-BRD003), respec-
tively, with BsmBI compatible overhangs, using standard protocols. Cells were
expanded and sorted after 5 days to establish the two cell lines clones: BPCas9+GFP
+B2M−/− and BPCas9+GFP+Thy1.1+B2M+/+. Flow cytometry was used to conﬁrm the
deletion of B2M and the expression of Thy1.1 in the two clones 5 days after sorting
and only 0% B2M and 100% Thy1.1-positive cells were kept.
Mice and tumor transplant and tissue collection. Female C57BL/6 mice
8–9 weeks of age were purchased form Jackson Laboratory and were housed at
Massachusetts General Hospital under SPF conditions. Animal use followed pro-
tocols approved by the Massachusetts General Hospital Institutional Animal Care
and Use Committee (IACUC). BPCas9+GFP+B2M−/− and BPCas9+GFP+Thy1.1+B2M+/+
cells (1 × 106) were mixed in a 1:1 ratio and injected intradermally into the right
ﬂank. For depletion assay, mice were treated with intraperitoneal injection of 200
µg anti-mouse NK1.1 (clone PK136, BioXCell, BP0036) on days 2 and 5 following
tumor transplantation. On day +7, mice were sacriﬁced and tumors were dissected
manually. Tumors were minced and digested with 2 mg/ml collagenase I (Sigma,
C0130), 2 mg/mg hyaluronidase (Sigma, H3506) and 25 µg/ml Dnase (Promega) by
incubating at 37 °C for 30 min with gentle mixing. Digests were then passed
through 50 µm ﬁlter, counted and prepared for ﬂow cytometry staining.
Flow cytometry and antibodies. Monoclonal antibodies speciﬁc for CD16 and
CD32 (Biolegend, 101302; 1:100) were used for blockade of Fc receptors before
staining. The antibodies used for cell surface labeling were AF647 anti-mouse H-
2Kb/H-2Db (Biolegend, 114612; 1:100), APC anti-mouse Thy1.1 (Biolegend,
202526; 1:100), and PE anti-mouse NK1.1 (Biolegend, 108707; 1:100). Intracellular
staining of unlabeled B2M (Abcam, ab75853; 1:100) following staining with a
secondary APC anti-rabbit IgG (R&D systems, F0111) was performed using a
staining buffer set (eBioscience) according to the manufacturer’s instructions.
Samples were analyzed by CytoFLEX ﬂow cytometer (Beckman Coulter).
In vivo competition assay. For the in vivo competition assay, BPCas9+GFP+B2M−/−
and BPCas9+GFP+Thy1.1+B2M+/+ cells were mixed in a 1:1 ratio and intradermally
injected into the right ﬂank of recipient mice. Tumors were collected on day 7 post
transplantation and the ratio between each clone (GFP+Thy1.1− or GFP+Thy1.1+)
was determined based on ﬂow cytometry analysis and was normalized based on the
initial ratio measured on the day of tumor inoculation. The following formula was
used to calculate the percentage change from baseline for the two clones: (1−(B2M−/−
sample %/B2M−/− baseline %)/(B2M+/+ sample %/B2M+/+ baseline %)) × 100.
Code availability. Information on Firehose can be found at http://www.
broadinstitute.org/cancer/cga/Firehose. Software used in this study is available as
standard pipelines on Firehose. For individual download, software used in this
study can be found at http://www.broadinstitute.org/cancer/cga. ReCapSeg and
AllelicCapseg can be downloaded from http://www.broadinstitute.org/cancer/cga/
acsbeta. Mutect2 is found at https://software.broadinstitute.org/gatk/gatkdocs/
org_broadinstitute_gatk_tools_walkers_cancer_m2_MuTect2.php. PhyloWGS
v1.0-rc1 can be found at https://github.com/morrislab/phylowgs. NetMHCpan 2.4
can be found at http://www.cbs.dtu.dk/services/NetMHCpan-2.4/42.
Data availability. The Van Allen data set referenced during the study is available
in a public repository from dbGAP database (https://www.ncbi.nlm.nih.gov/gap),
under accession code phs000452.v2.p1. The Hugo data set was provided to us by
Roger S. Lo (rlo@mednet.ucla.edu) and is not available on a public repository. All
sequencing data from this study have been deposited in dbGap database (https://
www.ncbi.nlm.nih.gov/gap), under accession code phs001427.v1.p1.
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